eligibility_summary
Include: adults (≥18) with R/R MM (IMWG), measurable disease, ≥4 prior lines incl PI, IMiD, anti‑CD38, >100 d post‑auto SCT, ECOG≤2, adequate organ function, controlled HIV/hepatitis, stable CNS ok, consent/contraception. Exclude: plasma cell leukemia/AL/POEMS/Waldenström, prior anti‑BCMA bispecifics or CELMoDs, allo‑SCT, active infection/bleeding, unstable liver, unresolved ≥G2 AEs, strong CYP3A4/5 drugs, >10 mg steroids, other anticancer/investigational therapy, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Teclistamab (Tecvayli) plus iberdomide. Teclistamab is a subcutaneous bispecific T‑cell–redirecting monoclonal antibody (anti‑BCMA×CD3). Iberdomide (CC‑220) is an oral cereblon E3 ligase modulator (CELMoD). Mechanisms: Teclistamab binds BCMA on malignant plasma cells and CD3 on T cells to activate and redirect T‑cell cytotoxicity against myeloma cells. Iberdomide binds cereblon to promote ubiquitination/degradation of IKZF1 (Ikaros) and IKZF3 (Aiolos), directly impairing myeloma survival and enhancing T‑ and NK‑cell activation while reducing pro‑tumor cytokines. Targeted cells/pathways: BCMA+ plasma cells, CD3+ T cells, cereblon/CRL4 E3 ubiquitin ligase pathway and IKZF1/3 transcriptional program, immune microenvironment including T‑cell activation/exhaustion and T regulatory cells. Soluble BCMA (sBCMA) is assessed as a biomarker.